Publications by authors named "S Pitroda"
Background And Purpose: Stereotactic ablative body radiotherapy (SABR) is an effective treatment for localized renal cell carcinoma (RCC). However, the role of primary site SABR for locally recurrent or metastatic RCC is unclear. Here, we report outcomes of primary SABR across a diverse cohort of localized, recurrent, and metastatic RCC patients treated at our institution.
View Article and Find Full Text PDFArticle Synopsis
- The study finds that the YTHDF1 protein, which reads N6-methyladenosine on RNA, plays a crucial role in cancer progression and is upregulated in dendritic cells (DCs) after radiotherapy (RT).
- High levels of YTHDF1 in DCs are linked to worse patient outcomes during RT, while removing or inhibiting YTHDF1 boosts the effectiveness of radiation therapy in cancer models.
- The research uncovers a regulatory mechanism between YTHDF1 and the STING signaling pathway, suggesting that targeting YTHDF1 could improve cancer treatment strategies such as RT and radioimmunotherapy.
Background: Immunotherapy in combination with chemotherapy is first-line treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC). Growing evidence suggests that radiation, specifically stereotactic body radiation therapy (SBRT), may enhance the immunogenic response as well as cytoreduce tumor burden. The primary objective of the study is to determine the progression free survival for patients with newly diagnosed ES-SCLC treated with combination multisite SBRT and chemo-immunotherapy (carboplatin, etoposide, and durvalumab).
View Article and Find Full Text PDFRecent studies have linked elevated tumor aneuploidy to anti-tumor immune suppression and adverse survival following immunotherapy. Herein, we provide supportive evidence for tumor aneuploidy as a biomarker of response to immunotherapy in patients with non-small cell lung cancer (NSCLC). We identify a dose-response relationship between aneuploidy score and patient outcomes.
View Article and Find Full Text PDFBackground: Stereotactic body radiotherapy (SBRT) is safe and effective for treatment of extracranial metastatic disease, but its safety when combined with immune checkpoint inhibitors (ICI) has not yet been comprehensively reported. Here we report adverse events (AEs) associated with combined SBRT and ICI using prospectively-collected data on patients in three trials investigating multi-site SBRT combined with ICI.
Methods: Patients were included from three prospective trials of ICI (pembrolizumab; nivolumab/urelumab or nivolumab/cabiralizumab; nivolumab/ipilimumab) with SBRT to 1-4 sites.